The association between psoriasis and erectile dysfunction is one of the more consistently reproduced findings in dermatologic epidemiology, and one of the least discussed inside the dermatology clinic. Psoriasis affects roughly 2% of the global population and is no longer understood as a disease confined to the skin. It is a systemic inflammatory condition with measurable effects on the vascular endothelium — and an erection is, mechanically, an endothelial event. Placed side by side, the two conditions stop looking like coincidence and start looking like shared biology.
The Epidemiological Signal Is Consistent
Three independent meta-analyses have examined this question, and they agree.
Wu and colleagues pooled the available observational data in The Journal of Sexual Medicine in 2018 and found a significant association between psoriasis and erectile dysfunction across the included studies [1]. The following year, Zhao and colleagues published a separate systematic review and meta-analysis in International Journal of Impotence Research, concluding that men with psoriasis show a high prevalence of erectile dysfunction relative to controls [2]. An earlier Chinese-language meta-analysis by Zhang and colleagues had already pointed in the same direction [3].
Three caveats matter when reading this literature. First, most contributing studies are cross-sectional, which establishes association rather than causation. Second, erectile function is usually captured with the International Index of Erectile Function questionnaire, a validated instrument but a self-reported one. Third, several cohorts report that the association tracks with disease severity — men with more extensive or longer-standing psoriasis report worse erectile function than those with limited disease. A dose-response pattern of that kind is one of the classical arguments for a real underlying mechanism rather than a statistical artefact.
Why Systemic Inflammation Reaches the Penile Arteries
The mechanistic case rests on the endothelium. Erection depends on endothelial nitric oxide synthase producing nitric oxide, which raises intracellular cyclic GMP in the smooth muscle of the corpora cavernosa, relaxing it and allowing arterial inflow. Anything that reduces nitric oxide bioavailability degrades that process.
Chronic inflammation does exactly that. The cytokines central to psoriasis — tumour necrosis factor alpha and the interleukin-17 and interleukin-23 axis — promote oxidative stress, increase reactive oxygen species that scavenge nitric oxide directly, and impair endothelial nitric oxide synthase function. The result is a vascular bed that dilates less readily than it should.
This is not theoretical. De Simone and colleagues measured flow-mediated dilation, a non-invasive marker of endothelial function, in psoriasis patients and matched controls, and documented impaired endothelial function in the psoriasis group [4]. A broader review by Shaharyar and colleagues in Atherosclerosis surveyed the subclinical cardiovascular literature in plaque psoriasis and found that several studies reported reduced flow-mediated dilation and increased carotid intima-media thickness in these patients [5].
The anatomical point is what makes this clinically urgent. The cavernosal arteries are roughly 1–2 mm in diameter — considerably narrower than the coronary arteries. The same degree of endothelial impairment produces symptoms in the penile circulation earlier than it does in the heart. Erectile dysfunction in a man with systemic inflammatory disease is not only a quality-of-life problem; it is a vascular finding that deserves a cardiovascular workup.
The Shared Metabolic Terrain
Psoriasis does not travel alone. It clusters with obesity, metabolic syndrome, type 2 diabetes, dyslipidaemia, hypertension, smoking and depression. Every one of those is independently associated with erectile dysfunction.
This means some of the observed association is confounded, and honest reading of the data requires saying so. But confounding and mechanism are not mutually exclusive. Adipose tissue is itself an inflammatory organ; insulin resistance impairs endothelial nitric oxide synthase; psoriasis raises systemic inflammatory burden on top of both. These pathways converge rather than compete.
The practical implication is straightforward. A man presenting with psoriasis and new erectile dysfunction warrants a metabolic assessment — fasting glucose or HbA1c, a lipid panel, blood pressure, and consideration of testosterone — before the symptom is treated in isolation. The erectile complaint is frequently the first thing that brings him to a doctor at all.
Genital Psoriasis and the Burden Nobody Asks About
A substantial minority of psoriasis patients experience genital involvement at some point, and it is systematically under-recognised. Kelly and Ryan, reviewing the topic in American Journal of Clinical Dermatology, note that severity indices designed for plaque psoriasis — which score by body surface area — badly understate the impact of a small but anatomically critical area of involvement [6].
Here the pathway to erectile dysfunction is different. Fissuring, discomfort during intercourse, visible lesions and anticipatory embarrassment produce avoidance, and avoidance produces performance anxiety that is psychogenic rather than vascular in origin. In practice, many men carry both mechanisms simultaneously. Distinguishing them matters, because they respond to different interventions. Clinicians rarely ask about genital involvement directly, and patients rarely volunteer it.
What Treating the Skin Does — and Does Not Do
If inflammation drives the vascular change, controlling inflammation should help. The evidence is early but pointed in the expected direction.
AlMutairi and Eassa conducted a randomised controlled trial comparing ixekizumab with secukinumab in adults with genital psoriasis and assessed the impact on sexual activity alongside lesion severity [7]. On the vascular side, Costa and colleagues ran a prospective pilot in Journal of Dermatological Treatment in 2026, assessing endothelial function by flow-mediated dilation and estimating nitric oxide bioavailability before and after 12 weeks of methotrexate therapy — a design that treats the endothelium, not just the plaque, as the outcome of interest [8].
What this evidence does not support is the assumption that clearing the skin reverses established erectile dysfunction. Once endothelial damage is structural rather than purely functional, anti-inflammatory therapy alone is unlikely to restore erectile capacity. These become two related problems requiring two treatments.
PDE5 inhibitors remain the first-line pharmacological option, and they act on the same pathway the inflammation degrades: by blocking the breakdown of cyclic GMP, they amplify whatever nitric oxide signal remains. For men whose erectile dysfunction has an endothelial basis, clinical studies suggest that continuous daily low-dose PDE5 inhibition may support endothelial function more consistently than intermittent on-demand dosing, though the long-term vascular evidence is still developing. Vitamin D status is a second thread worth noting: deficiency is common in psoriasis and has independently been linked to erectile dysfunction in observational work, and some men experience benefit from correcting it. Neither approach is a cure, and both belong in a supervised treatment plan rather than a self-directed one.
Conclusion
Psoriasis and erectile dysfunction are connected by inflammation acting on the vascular endothelium, and the connection is strong enough that erectile complaints in a psoriasis patient should trigger a cardiovascular and metabolic assessment rather than a reflex prescription. The epidemiological association is reproducible across meta-analyses, the mechanism is biologically coherent, and the shared metabolic risk factors reinforce rather than explain away the finding. Men with psoriasis who notice a change in erectile function are observing something real about their vascular health, and it is worth investigating properly. You can read more in our blog library on the vascular drivers of erectile dysfunction.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. Their daily formulation, EPIQ CHEWS, combines low-dose dual PDE5 inhibition with vitamin D3 and K2.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Wu T, Duan X, Chen S, et al. Association Between Psoriasis and Erectile Dysfunction: A Meta-Analysis. The Journal of Sexual Medicine. 2018;15(6):839-847. doi:10.1016/j.jsxm.2018.04.630
- Zhao S, Wang J, Xie Q, et al. High prevalence of erectile dysfunction in men with psoriasis: evidence from a systematic review and meta-analysis. International Journal of Impotence Research. 2019;31(2):74-84. doi:10.1038/s41443-018-0093-8
- Zhang FB, Wu BC, Xie LB, Jiang R. Correlation of psoriasis with erectile dysfunction: A meta-analysis. Zhonghua Nan Ke Xue. 2017;23(3):256-261. PMID: 29706048
- De Simone C, Di Giorgio A, Sisto T, et al. Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. European Journal of Dermatology. 2011;21(4):510-514. doi:10.1684/ejd.2011.1324
- Shaharyar S, Warraich H, McEvoy JW, et al. Subclinical cardiovascular disease in plaque psoriasis: association or causal link? Atherosclerosis. 2014;232(1):72-78. doi:10.1016/j.atherosclerosis.2013.10.023
- Kelly A, Ryan C. Genital Psoriasis: Impact on Quality of Life and Treatment Options. American Journal of Clinical Dermatology. 2019;20(5):639-646. doi:10.1007/s40257-019-00447-5
- AlMutairi N, Eassa BI. A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis. Expert Opinion on Biological Therapy. 2021;21(2):297-298. doi:10.1080/14712598.2021.1843629
- Costa TAS, Bonilha I, Medorima STK, et al. Effect of methotrexate on endothelial function in psoriasis patients. Journal of Dermatological Treatment. 2026;37(1):2663649. doi:10.1080/09546634.2026.2663649
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.